Skip to main content

Alumis Inc.

ALMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001847367

In the last 90 days, Alumis Inc. insiders filed 1 open-market purchase and 7 sales; 198 institutions reported holding it in 13F filings for Q2 2026, worth $3.32B in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 2:43 PM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: $243.3M (1011.7% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Alumis Inc., annual
Line itemFY2025FY2024
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
ReportedJan 9, 2026Feb 6, 2025
Revenue$24.1M–
Operating expenses$477.9M$300.8M
Research and development$386.0M$265.6M
Selling, general and administrative$91.9M$35.2M
Operating income-$453.8M-$300.8M
Income tax-$8.56M$0
Net income-$243.3M-$294.2M
EPS, basic$-2.86$-10.38
EPS, diluted$-2.86$-10.38
Weighted shares, basic85.0M28.3M
Weighted shares, diluted85.0M28.3M
Margins and growth
Operating margin-1886.9%–
Net margin-1011.7%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Alumis Inc., annual
Line itemFY2025FY2024
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
ReportedJan 9, 2026Feb 6, 2025
Cash and equivalents$89.7M$169.5M
Short-term investments$218.8M$118.7M
Total current assets$318.2M$306.2M
Property, plant and equipment$18.2M$21.0M
Total assets$411.9M$341.0M
Accounts payable$10.1M$9.62M
Total current liabilities$73.3M$50.9M
Total liabilities$110.6M$80.9M
Shareholders' equity$301.3M$260.1M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Alumis Inc., annual
Line itemFY2025FY2024
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
ReportedJan 9, 2026Feb 6, 2025
Operating cash flow-$369.5M-$255.1M
Capital expenditures$653.0K$1.73M
Free cash flow-$370.2M-$256.8M
Depreciation and amortization$3.50M$3.15M
Stock-based compensation$43.5M$19.5M
Share buybacks$17.0K$6.00K
Investing cash flow$287.9M-$113.8M
Financing cash flow$2.07M$492.4M
Ratio
Stock-based compensation, % of revenue181.0%–

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Alumis Inc. reports no single share count on its 10-K and 10-Q covers. Companies with several share classes report one count per class, which this data doesn't include.

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.